The Western diet (WD) not only promotes lesion growth but also activates specific macrophage markers (CD80 and CD206), ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

One of the key immune cells that does this is called the macrophage. These macrophages live in every organ or tissue and work ...

The presented data show that PHST001, through potent CD24 binding, promotes macrophage-induced phagocytosis in a number of cancer cells and significantly shrinks tumors in vivo. In addition, PHST001 ...

Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...

Department of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, United States ...

This study demonstrates that global or adipose tissue-specific knockout of CIDEC/FSP27 significantly reduces AAA incidence ...

Boston Children's Hospital and Harvard Medical School researchers have discovered a neuroimmune communication pathway that ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third ...

Preclinical data have shown the ability of AT-02 to bind to multiple amyloid types in major organs and induce macrophage mediated amyloid phagocytosis and amyloid removal. AT-02 is currently being ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...